soul trial oral semaglutide cardiovascular outcomes 2024 results nejm Reduces Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary From the Randomized Semaglutide and Cardiovascular Outcomes in

Name: soul trial oral semaglutide cardiovascular outcomes 2024 results nejm Reduces Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary From the Randomized Semaglutide and Cardiovascular Outcomes in
Brand: matisco.be
SKU: 43618314998
Price: 22.97 USD
Availability: InStock
Rating: 4.3609 (24 reviews)

SKU: 43618314998

4.4

USD22.97 USD63.97

Pay in 4 interest-free payments of $5.74 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Live Spec

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes New England Journal of Medicine NEJM Editorial Fellow Harleen Marwah, MD, summarizes the SOUL trial. Visit NEJM.org for the full trial results. #ACC25 #Cardiology #ClinicalTrials #MedTok #NEJM Canadian Perspectives 2025 Whiteboard on the SOUL Trial Oral Semaglutide and Cardiovascular Outcomes in High Risk Type 2 Diabetes New England Journal of Medicine

Store: matisco.be · Domain: matisco.be

Description

Big pharma players including Roche, AstraZeneca and Regeneron eyeing the next wave of obesity growth

Wegovy works best when used as part of a comprehensive weight loss program that includes healthy eating combined with regular exercise

Manufacturing Excellence & Global Capabilities Our modern manufacturing infrastructure enables us to serve domestic and international healthcare markets with efficiency and consistency